{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:26:36Z","timestamp":1791851196959,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1136\/ard.2010.148759","type":"journal-article","created":{"date-parts":[[2011,5,14]],"date-time":"2011-05-14T00:45:02Z","timestamp":1305333902000},"page":"1575-1580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":201,"title":["Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries"],"prefix":"10.1016","volume":"70","author":[{"given":"Katerina","family":"Chatzidionysiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Lukina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Tarp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Gabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet L C M","family":"van Riel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan C","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gomez-Reino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Tomsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2010.148759_bib1","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.148759_bib2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.148759_bib3","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.148759_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.rdc.2004.01.006","article-title":"B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.","volume":"30","author":"Edwards","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard.2010.148759_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo\u2011controlled, phase III trial.","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.148759_bib6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.148759_bib7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.148759_bib8","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.148759_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02849902","article-title":"Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis.","volume":"24","author":"Lundquist","year":"2007","journal-title":"Adv Ther"},{"key":"10.1136\/ard.2010.148759_bib10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.148759_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/ard.2010.135376","article-title":"The need for personalised medicine for rheumatoid arthritis.","volume":"70","author":"Isaacs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.148759_bib12","first-page":"1596","article-title":"Interim results of the Russian register of anti-B-cell antibodies (rituximab) in rheumatoid arthritis","volume":"16","author":"Lukina","year":"2008","journal-title":"Russ Med J"},{"key":"10.1136\/ard.2010.148759_bib13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00296-005-0054-7","article-title":"Performance study of patients using traditional anti-rheumatic drugs in combination with infliximab: the Finnish perspective","volume":"26","author":"Nordstr\u00f6m","year":"2006","journal-title":"Rheum Int"},{"issue":"5 Suppl 39","key":"10.1136\/ard.2010.148759_bib14","first-page":"S205","article-title":"DANBIO: a nationwide registry of biological therapies in Denmark.","volume":"23","author":"Hetland","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2010.148759_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 39","key":"10.1136\/ard.2010.148759_bib16","first-page":"S195","article-title":"Rheumatoid arthritis registries in Sweden.","volume":"23","author":"van Vollenhoven","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"5 Suppl 39","key":"10.1136\/ard.2010.148759_bib17","first-page":"S188","article-title":"A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases.","volume":"23","author":"Kvien","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 2","key":"10.1136\/ard.2010.148759_bib18","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1136\/ard.62.suppl_2.ii30","article-title":"Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.","volume":"62","author":"Flendrie","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.148759_bib19","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2006.067660","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.","volume":"66","author":"Carmona","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.148759_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijmedinf.2005.07.043","article-title":"Some principles of the development of a clinical database\/national register of selected inflammatory rheumatic diseases in the Czech Republic.","volume":"75","author":"Dostal","year":"2006","journal-title":"Int J Med Inform"},{"key":"10.1136\/ard.2010.148759_bib21","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.148759_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.148759_bib23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","article-title":"Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.","volume":"48","author":"Quartuccio","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2010.148759_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.0300-9475.2004.01441.x","article-title":"Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.","volume":"60","author":"Szodoray","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1136\/ard.2010.148759_bib25","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","article-title":"Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.","volume":"46","author":"De Vita","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.148759_bib26","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.22520","article-title":"B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.","volume":"56","author":"Finckh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.148759_bib27","first-page":"S899","article-title":"The effectiveness of Rituximab in patients with rheumatoid arthritis (RA) who previously failed one or two anti-TNFs as compared with the effectiveness of switching between anti-TNFs: a registry study [abstract]","volume":"58","author":"van Vollenhoven","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724191583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724191583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2010.148759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:08:55Z","timestamp":1737248935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724191583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0003496724191583"],"URL":"https:\/\/doi.org\/10.1136\/ard.2010.148759","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2010.148759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}